Edwards Lifesciences (EW) Non-Current Debt (2009 - 2026)

Edwards Lifesciences has reported Non-Current Debt for 18 years, with the latest figure at $598.7 million in Q2 2026.

• On a quarterly basis, Non-Current Debt changed 0.12% year-over-year to $598.7 million in Q2 2026; TTM through Jun 2026 was $598.7 million, a 0.12% change from a year earlier, with the FY2025 full-year figure at $598.3 million, changed 0.1% from the prior year.
• Non-Current Debt was $598.7 million for Q2 2026 at Edwards Lifesciences, roughly flat from $598.5 million in the prior quarter.
• The five-year high for Non-Current Debt was $598.7 million in Q2 2026, with the low at $595.9 million in Q1 2022.
• Average Non-Current Debt over 5 years is $597.3 million, with a median of $597.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Non-Current Debt gained 0.12% in 2022, then gained 0.1% in 2025.
• Over 5 years, Non-Current Debt stood at $596.3 million in 2022, then rose by 0.12% to $597.0 million in 2023, then increased by 0.12% to $597.7 million in 2024, then rose by 0.1% to $598.3 million in 2025, then grew by 0.07% to $598.7 million in 2026.
• The last three Non-Current Debt figures came in at $598.7 million (Q2 2026), $598.5 million (Q1 2026), and $598.3 million (Q4 2025), per Business Quant data.